Oracle Sits Far Below Wall Street's Target. Here's What Gets It There.

Oracle (NYSE:ORCL | ORCL Price Prediction) currently trades at $142.07, while the Wall Street consensus target is $246.43.

24/7 Wall Street • Aug 21, 2026

Michael Burry Says the AI Buildout Is Repeating 2008: ‘The Shenanigans Are Apparent Today'

Michael Burry issued a fresh warning Friday that the AI data center boom mirrors the structural excesses that preceded 2008, arguing that circular financing, off-balance-sheet vehicles and captive insurers are quietly building leverage across the ecosystem.

24/7 Wall Street • 20 hours ago

Oracle: Cheap, But Too Early - The Real Inflection Comes In 2027

Oracle Corporation remains a patient buy, but I expect a long grind before significant upside materializes, with mid-2027 as the likely inflection point. ORCL appears cheap on forward PEG (0.61) and P/E (17.7), yet price appreciation is unlikely until AI sentiment stabilizes and sector headwinds subside. Fundamentals point to a transformative revenue ramp in FY27, driven by a massive AI backlog and Oracle Cloud Infrastructure growth to $32B.

Seeking Alpha • Aug 20, 2026

These 2 Computer and Technology Stocks Could Beat Earnings: Why They Should Be on Your Radar

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks Investment Research • Aug 20, 2026

Oracle Price Prediction: Can Its $638 Billion Backlog Send The Stock Back Toward $250?

Oracle's (NYSE:ORCL | ORCL Price Prediction) remaining performance obligations vaulted to $638 billion in Q4 FY2026, an unprecedented backlog that reframes the investment case.

24/7 Wall Street • Aug 19, 2026

Oracle stock has become a bargain, but a risky pattern has emerged

Oracle stock remains under intense pressure this week, extending a steep decline that began after the shares peaked at $345 in September last year. The stock has since plunged nearly 60% from its all-time high, with its valuation increasingly appearing attractive even as investors remain concerned about the company's rising debt burden and significant exposure to major customers such as OpenAI.

Invezz • Aug 19, 2026

Can Oracle Stock Really Surge 60% On Its Massive AI Backlog?

This article was written by Doug Nathman, with research by his team at Trefis.

Forbes • Aug 19, 2026

Oracle Health Expands Clinical AI Agent with Automated Coding, Dictation, and Chart Review

New AI capabilities help clinicians document faster, streamline professional fee coding, and surface relevant patient context AUSTIN, Texas, Aug. 19, 2026 /PRNewswire/ -- Oracle Health today announced new capabilities for Oracle Health Clinical AI Agent, now available in the U.S., that expand AI across clinical documentation, coding, and chart review workflows. The new capabilities automate professional fee coding for ambulatory workflows, enable physicians to dictate directly into clinical documentation, and assist with chart review by surfacing clinically relevant context across the patient record.

PRNewsWire • Aug 19, 2026

Oracle vs. Microsoft: Which Enterprise AI Stock Is the Better Buy?

ORCL's record AI backlog, strong cloud growth and discounted valuation give it an edge over MSFT as enterprise AI demand accelerates.

Zacks Investment Research • Aug 19, 2026

Oracle Just Raised Its Dividend for a 12th Straight Year to $2 a Share, Even as AI Spending Pressures Free Cash Flow. Is Larry Ellison's Payout Still Safe?

Oracle's earnings, backlog, and modest payout ratio provide a solid cushion for the dividend. Negative free cash flow and a rising debt load make the dividend's future increasingly dependent on whether Oracle can successfully monetize its heavy AI investments.

The Motley Fool • Aug 18, 2026